Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
2024 · Scientific Reports · 4 citations
https://doi.org/10.1038/s41598-024-56195-y
Mayo Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
13
Papers
154
Citations
5
h-index
5
i10-index
Hilary R. Teaford is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Chronic Kidney Disease and Diabetes & Dialysis and Renal Disease Management & Acute Kidney Injury Research. The author has an h-index of 5, co-authored 12 publications.
ORCID: 0000-0002-2120-7380Click to start Chat